Breaking Down Allogene Therapeutics: 5 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Five analysts have recently evaluated Allogene Therapeutics (NASDAQ:ALLO), with opinions ranging from bullish to bearish. The average 12-month price target has increased by 48.06% to $9.92. Analysts from Truist Securities, Stifel, HC Wainwright & Co., RBC Capital, and JP Morgan have provided updated ratings and price targets, reflecting their views on the company's market position and financial health.
May 15, 2024 | 7:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have mixed views on Allogene Therapeutics, with a notable increase in the average 12-month price target to $9.92. The company's financial metrics show challenges in revenue growth and net margin but strengths in ROE, ROA, and debt management.
The increase in the average price target and the mixed but generally positive analyst ratings suggest a potential short-term positive impact on ALLO's stock price. The company's strong ROE, ROA, and conservative debt management further support this outlook, despite challenges in revenue growth and net margin.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100